Evaluation of cutaneous manifestations in patients under treatment with thyroid disease

Turkderm - Turkish Archives of Dermatology and Venereology 2020;54:46-50

©Copyright 2020 by Turkish Society of Dermatology and Venereology
Turkderm - Turkish Archives of Dermatology and Venereology published by Galenos Yayınevi.

Address for Correspondence/Yazışma Adresi:
Ersoy Acer MD, Eskişehir Osmangazi University Faculty of Medicine, Department of Dermatology, Eskişehir, Turkey
Phone: +90 506 714 75 74 E-mail: ersoyacer@hotmail.com
Received/Geliş Tarihi: 13.09.2019 Accepted/Kabul Tarihi: 21.02.2020

ORCID: orcid.org/0000-0002-6041-6636

Orijiinal Araftırma

Amaç:

Thyroid diseases often cause various findings in hair, skin and nails. Some of them may be regressed by the treatment of thyroid disease. We aimed to evaluate the cutaneous manifestations in patients with thyroid disease under treatment.

Materials and Methods:

This cross-sectional study included 97 consecutive patients with thyroid disease under treatment and 50 healthy controls. Thyroid disease was classified as autoimmune and non-autoimmune. All skin findings and dermatological diseases were recorded.

Results:

Of the patient group, 56 (57.7%) had autoimmune, 41 (43.3%) had non-autoimmune thyroid disease. Eighty-four (86.4%) patients were under thyroid hormone therapy and 13 (23.6%) patients were under anti-thyroid therapy. 73.2% of the autoimmune group, 71.4% of the non-autoimmune group and 52% of the control group had at least one cutaneous manifestation (p=0.05). Xerosis (p=0.026), pruritus (p=0.00), facial erythema (p=0.036), flushing (p=0.004), dry hair (p=0.008), brittle nails (p=0.02), dry nails (p=0.013) and longitudinal streaking on nails (p=0.02) were more frequent in the autoimmune group than in the non-autoimmune and control group. Alopecia (p=0.00) was more frequent in the non-autoimmune group. Furthermore diffuse hyperhidrosis (p=0.016), thinning of nails (p=0.059) and rosacea disease (p=0.03) were more common in the patient group than in the control group. At least one cutaneous manifestation, xerosis and various nail findings were more common in patients under thyroid hormone therapy than in patients under anti-thyroid therapy, but there was no statistically significant difference.

Conclusion:

These findings have shown that various cutaneous manifestations can also be seen in patients with thyroid disease under treatment. We believe that further studies comparing thyroid patients who received and did not receive treatment are necessary to clarify the effect of thyroid disease treatment on cutaneous manifestations.

Keywords:

Cutaneous manifestations, thyroid diseases, autoimmunity
Sonuç: Bu bulgular, tedavi altında tiroid hastalarında da çeşitli deri bulgularının görülebileceğini göstermiştir. Tiroid hastalığı tedavisinin kütanöz bulgular üzerindeki etkisini netleştirmek için tedavi altında olan ve olmayan tiroid hastalarını karşılaştıran daha ileri çalışmaların gerekli olduğu düşünüyoruz.

Anahtar Kelimeler: Kütanöz bulgular, tiroid hastalıkları, otoimmünite

Introduction

Thyroid hormones (TH) play an important role in maintaining normal functions of the skin, so the first signs of TH imbalance are often seen in the skin. TH affects proteoglycan synthesis in the skin by stimulating fibroblasts. They also play a regulatory role in epidermal differentiation through their effects on keratinocytes. Furthermore, TH are very important in hair formation and sebum production. Thyroid diseases often cause changes in hair, skin and nails. Therefore, dermatologists should be familiar with dermatological findings associated with thyroid diseases. Some of these findings may regress with the treatment of thyroid disease; but some findings especially related with autoimmunity may not regress.

To best of our knowledge, there is only one study evaluating cutaneous manifestations in patients with thyroid disease under treatment in the literature. In this study, we aimed to evaluate the cutaneous manifestations in patients with thyroid disease under treatment.

Materials and Methods

Ninety-seven consecutive patients with thyroid disease and 50 healthy controls aged over 18 years were included in this cross-sectional study. Patients were referred by endocrinology department of our hospital. Thyroid patients with untreated, under treatment for less than 1 year and newly diagnosed were excluded. Other exclusion criteria were pregnancy, lactation and having any other systemic diseases and medications. Ethical approval was received from the Eskişehir Osmangazi University, Non-interventional Clinical Research Ethics Committee (approval number: 43, date: 23.07.2019). Informed consent was obtained from all participants.

Graves’ disease and Hashimoto’s thyroiditis are autoimmune, whereas other diseases such as nodular and diffuse goiters are non-autoimmune thyroid diseases. Patients with thyroid disease were classified as autoimmune and non-autoimmune by an endocrinologist. Dermatological examination of all patients and controls were performed by the same dermatologist. All cutaneous manifestations and dermatological diseases were recorded.

Statistical Analysis

IBM SPSS Statistics 21.0 (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.) software was used for the data analyses. Continuous data was presented as mean ± standard deviation and median. Categorical data was presented in percentage (%). Pearson’s chi-square and Pearson’s exact chi-square was used to analyze the cross-tables. P<0.05 value was accepted to be statistically significant.

Results

The study included 97 patients with thyroid disease [82 (84.5%) female, 15 (15.5%) male] and 50 healthy controls [38 (76.0%) female, 12 (24.0%) male]. Mean age of patient group was 52.23±12.52 years and mean age of control group was 54.40±14.83 years. The groups were similar in terms of age and gender (p>0.05). Mean disease duration was 7.84±2.14 years in patient group. Of 97 patients with thyroid disease, 56 (57.7%) were autoimmune, 41 (43.3%) were non-autoimmune. Eighty-four (86.4%) were on thyroid hormone therapy and 13 (23.6%) were on anti-thyroid therapy. Mean treatment duration was 6.29±1.98 years. At least one cutaneous manifestation was present in 73.2% of autoimmune group, 71.4% of non-autoimmune group and 52% of control group (p=0.05). Xerosis (p=0.026), pruritus (p=0.00), facial erythema (p=0.036), flushing (p=0.004), dry hair (p=0.008), brittle nails (p=0.02), dry nails (p=0.013), longitudinal streaking on nails (p=0.02) were more frequent in the autoimmune group than the non-autoimmune and control groups. Alopecia (p=0.00) was more frequent in non-autoimmune group (Table 1). In addition, in the patient group, diffuse hyperhidrosis (p=0.016), nail thinning (p=0.059) and rosacea (p=0.03) were more frequent than the control group. When patient group were evaluated according to treatment; at least one cutaneous manifestation, xerosis, facial erythema and various nail findings were more common in thyroid hormone therapy group, whereas pruritus, diffuse hyperhidrosis and alopecia were more common in anti-thyroid therapy group but there was no statistically significant difference (Table 2).

Discussion

TH play important roles in maintaining normal skin functions. The effect of TH in cutaneous biology including epidermis, dermis and hair has been shown. Cutaneous manifestations usually occur after the development of thyroid disease; but they may be the first sign of thyroid disease. They can be divided into two main categories; 1. Direct effect of TH on skin tissues 2. Skin diseases caused by autoimmune etiology. Some of these findings may regress with the treatment of thyroid disease. Previous studies have evaluated skin findings in thyroid patients before treatment. In these studies, at least one cutaneous manifestation was found in 81% and 56.8% of patients with thyroid disease. In our study, skin findings before treatment were not evaluated and 72.1% of patients with thyroid disease on treatment had at least one cutaneous manifestation. Thyroid diseases may cause various symptoms in hair, skin and nails.

Different cutaneous manifestations may be seen in hypothyroidism and hyperthyroidism. In our study, there was no thyroid hormone levels of participants but they were categorized by thyroid hormone therapy and anti-thyroid therapy groups. At least one cutaneous manifestation, xerosis, facial erythema and various nail findings were more common in thyroid hormone therapy group, whereas pruritus, diffuse hyperhidrosis and alopecia was more common in anti-thyroid therapy group but there was no statistically significant difference. This results may be related to the fact that the number of participants in the groups were not similar. The skin is characteristically cold, xerotic and pale in hypothyroidism. The cause of cold skin is peripheral vasoconstriction. Xerosis is
Table 1. Cutaneous manifestations in autoimmune, non-autoimmune and control groups

|                                      | Autoimmune group (n=41), n (%) | Non-autoimmune group (n=56), n (%) | Control group (n=50), n (%) | p*          |
|--------------------------------------|-------------------------------|-----------------------------------|-----------------------------|------------|
| At least one cutaneous manifestation | 30 (73.2)                     | 40 (71.4)                         | 26 (52.0)                   | 0.05       |
| Xerosis                              | 18 (43.9)                     | 23 (41.1)                         | 10 (20.0)                   | 0.026      |
| Pruritus                              | 17 (41.5)                     | 18 (32.1)                         | 2 (4.0)                     | 0.00       |
| Moist skin                           | 0                             | 0                                 | 0                           | -          |
| Yellow skin                          | 0                             | 0                                 | 0                           | -          |
| Diffuse hyperhidrosis                | 4 (9.8)                       | 6 (10.7)                          | 0 (0)                       | 0.062      |
| Palmoplantar hyperhidrosis           | 1 (2.4)                       | 1 (1.8)                           | 0 (0)                       | 0.747      |
| Palmoplantar hyperkeratosis          | 0                             | 0                                 | 0                           | -          |
| Facial erythema                      | 9 (22.0)                      | 9 (16.1)                          | 2 (4.0)                     | 0.036      |
| Flushing                              | 7 (17.1)                      | 3 (5.4)                           | 0 (0)                       | 0.004      |
| Periorbital edema                    | 2 (4.9)                       | 2 (3.6)                           | 0 (0)                       | 0.458      |
| Pretibial myxedema                   | 0                             | 0                                 | 0                           | -          |
| Diffuse edema                        | 1 (2.4)                       | 0 (0)                             | 0 (0)                       | 0.282      |
| Xanthelasma                          | 0 (0)                         | 1 (1.8)                           | 0 (0)                       | 1.00       |
| Local hyperpigmentation              | 1 (2.4)                       | 0 (0)                             | 1 (2.0)                     | 0.53       |
| Diffuse hyperpigmentation            | 0                             | 0                                 | 0                           | -          |
| Melasma                              | 2 (4.9)                       | 7 (12.5)                          | 2 (4.0)                     | 0.21       |
| Acanthosis nigricans                 | 0                             | 0                                 | 0                           | -          |
| Keratosis pilaris                    | 2 (4.9)                       | 1 (1.8)                           | 0 (0)                       | 0.27       |
| Eyebrow loss                         | 2 (4.9)                       | 4 (7.1)                           | 0 (0)                       | 0.17       |
| Alopecia                             | 29 (70.7)                     | 40 (71.4)                         | 18 (36.0)                   | 0.00       |
| Dandruff                             | 7 (17.1)                      | 8 (14.3)                          | 7 (14.0)                    | 0.90       |
| Hair graying                         | 38 (92.7)                     | 51 (91.1)                         | 48 (96.0)                   | 0.652      |
| Hair dryness                         | 6 (14.6)                      | 9 (16.1)                          | 0 (0)                       | 0.013      |
| Alopecia areata                      | 0 (0)                         | 1 (1.8)                           | 0 (0)                       | 1.00       |
| Seborrheic dermatitis                | 2 (4.9)                       | 3 (5.4)                           | 0 (0)                       | 0.26       |
| Shiny nails                          | 0 (0)                         | 1 (1.8)                           | 0 (0)                       | 1.00       |
| Soft nails                           | 3 (7.3)                       | 2 (3.6)                           | 0 (0)                       | 0.15       |
| Fine nails                           | 5 (12.2)                      | 6 (10.7)                          | 1 (2.0)                     | 0.13       |
| Brittle nails                        | 9 (22.0)                      | 11 (19.6)                         | 2 (4.0)                     | 0.02       |
| Dry nails                            | 3 (7.3)                       | 6 (10.7)                          | 0 (0)                       | 0.63       |
| Rough nails                          | 0 (0)                         | 1 (1.8)                           | 0 (0)                       | 1.00       |
| Onycholyis                           | 0 (0)                         | 2 (3.6)                           | 0 (0)                       | 0.33       |
| Distal separation                    | 0 (0)                         | 2 (3.6)                           | 0 (0)                       | 0.33       |
| Hyperkeratotic nails                 | 1 (2.4)                       | 1 (1.8)                           | 0 (0)                       | 0.74       |
| Transverse streaking on nails        | 1 (2.4)                       | 0 (0)                             | 0 (0)                       | 0.28       |
| Longitudinal streaking on nails      | 6 (14.6)                      | 5 (8.9)                           | 0 (0)                       | 0.02       |
| Clubbing                             | 0                             | 0                                 | 0                           | -          |
| Vitiligo                             | 0 (0)                         | 0 (0)                             | 1 (2.0)                     | 0.624      |
| Psoriasis                            | 1 (2.4)                       | 4 (7.1)                           | 0 (0)                       | 0.10       |
| Urticaria                            | 1 (2.4)                       | 2 (3.6)                           | 0 (0)                       | 0.63       |
| Rosacea                              | 7 (17.1)                      | 12 (21.4)                         | 3 (6.0)                     | 0.077      |
| Acne                                 | 2 (4.9)                       | 1 (1.8)                           | 1 (2.0)                     | 0.67       |
| Contact dermatitis                   | 4 (9.8)                       | 2 (3.6)                           | 2 (4.0)                     | 0.43       |

*p*Pearson’s chi-square
caused by peripheral vasoconstriction, reduction in epidermal steroid biosynthesis and sebaceous gland secretion and hypohidrosis. In previous studies, xerosis was observed in 37-45% of patients with thyroid disease, respectively. In our study, 42.2% of patients with thyroid disease had xerosis and it was the most common cutaneous manifestation. Pruritus (36.1%) was one of the most common cutaneous manifestation in our study similar to literature. Xerosis is the most common skin finding in hypothyroidism. In our study, xerosis was more common in thyroid hormone therapy group but there was no statistically significant difference in our study.

Skin is warm, soft, moist, smooth and also itchy in patients with hyperthyroidism. Warmth is caused by increased cutaneous blood flow. The moisture is a reflection of the underlying metabolic situation. In addition, facial erythema, flushing, palmar erythema, palmoplantar and diffuse hyperhidrosis may be seen in our study. In our study, facial erythema, flushing and diffuse hyperhidrosis were the common cutaneous manifestations similar to literature.

The hairs of scalp and body are usually dry, rough and brittle in hypothyroidism. Dry hair is one of the most common cutaneous findings in patients with thyroid disease. In our study, it was also one of the most common cutaneous manifestation. Patients with thyroid disease often have diffuse or partial alopecia. In our previous studies, alopecia was observed in 32.3%-45% of patients with thyroid disease. In our study, 72.1% of patients had alopecia. The high rate may be related with higher mean age of our patient group.

The loss of the lateral third of the eyebrows is one of the common cutaneous manifestations in patients with both hyperthyroidism and hypothyroidism. Six patients (6.2%) had this finding in our study. Localized and generalized hyperpigmentation may be seen in patients with hyperthyroidism. It is thought to be caused by increased pituitary adrenocorticotropic hormone. In addition, it has been reported that there is a relationship between melasma and thyroid autoimmunity. In a previous study, Dogra et al. reported that 18.7% of patients with hypothyroid had melasma and 6.2% had periorcular pigmentation. Melasma was more common in patients with thyroid disease (9.3%) in our study; but there was not statistically significant difference.

Patients with thyroid disease may have various nail findings. Dry, brittle, dull nails and longitudinal and transverse streakings on nails may be seen in hypothyroidism patients; whereas shiny, soft, friable nails and Plummer’s nails (distal onycholysis) in hyperthyroidism patients. In a previous study it was reported that 64% of thyroid disease patients had nail findings and the most common nail findings were longitudinal streaking on nails and distal onycholysis. Takir et al. reported that the most common nail findings were brittle nail (22.0%) and nail thinning (13.0%) in patients with thyroid disease. In our study, brittle nail (20.6%) and longitudinal streaking on nail (11.3%) were more common in thyroid patients. In addition nail findings were more common in thyroid hormone therapy group than anti-thyroid therapy group but the difference was not significant.

There may be a relationship between thyroid diseases and inflammatory skin diseases. It was reported that psoriasis and rosacea were associated with thyroid diseases in recent studies. In our study, rosacea (19.6%) was more frequent in patients with thyroid disease than healthy controls. Five (5.2%) patients had psoriasis; but there was no statistically significant difference.

Thyroid autoimmunity is often associated with various skin diseases such as vitiligo, pemphigus, chronic urticaria, dermatis herpetiformis, connective tissue diseases and alopecia areata. These skin findings may be related to thyroid hormone levels or T and/or B-cell activity.  

### Table 2. Cutaneous manifestations in anti-thyroid and thyroid hormone groups

| Manifestation                        | Anti-thyroid group (n=13), n (%) | Thyroid hormone group (n=84), n (%) | p*       |
|--------------------------------------|---------------------------------|------------------------------------|----------|
| At least one cutaneous               |                                 |                                    | 0.50     |
| Xerosis                              | 8 (61.5)                        | 62 (73.8)                          |          |
| Pruritus                             | 2 (15.4)                        | 39 (46.4)                          | 0.06     |
| Diffuse hyperhidrosis                | 7 (53.8)                        | 28 (33.3)                          | 0.21     |
| Palmar-plantar hyperhidrosis         | 2 (15.4)                        | 8 (9.5)                            | 0.61     |
| Facial erythema                      | 1 (7.7)                         | 17 (20.2)                          | 0.45     |
| Flushing                             | 1 (7.7)                         | 9 (10.7)                           | 1.00     |
| Periorbital edema                    | 0 (0)                           | 4 (4.8)                            | 0.64     |
| Diffuse edema                        | 0 (0)                           | 1 (1.2)                            | 1.00     |
| Xanthelasma                          | 0 (0)                           | 1 (1.2)                            | 1.00     |
| Local hyperpigmentation              | 0 (0)                           | 1 (1.2)                            | 1.00     |
| Melasma                              | 2 (15.4)                        | 7 (8.3)                            | 0.60     |
| Keratosis pilaris                    | 1 (7.7)                         | 2 (2.4)                            | 0.35     |
| Eyebrow loss                         | 0 (0)                           | 6 (7.1)                            | 0.59     |
| Alopecia                             | 9 (69.2)                        | 4 (30.8)                           | 1.00     |
| Dandruff                             | 1 (7.7)                         | 14 (16.7)                          | 0.47     |
| Yellowing                            | 10 (76.9)                       | 79 (94.0)                          | 0.07     |
| Hair dryness                         | 1 (7.7)                         | 14 (16.7)                          | 0.47     |
| Alopecia areata                      | 0 (0)                           | 1 (1.2)                            | 1.00     |
| Seborrheic dermatitis                | 0 (0)                           | 5 (6.0)                            | 0.61     |
| Shiny nails                          | 0 (0)                           | 1 (1.2)                            | 1.00     |
| Soft nails                           | 1 (7.7)                         | 4 (4.8)                            | 0.65     |
| Fine nails                           | 0 (0)                           | 11 (13.1)                          | 0.35     |
| Brittle nails                        | 2 (15.4)                        | 18 (21.4)                          | 0.73     |
| Dry nails                            | 1 (7.7)                         | 8 (9.5)                            | 1.00     |
| Rough nails                          | 0 (0)                           | 1 (1.2)                            | 1.00     |
| Onycholysis                          | 0 (0)                           | 2 (2.4)                            | 1.00     |
| Distal separation                    | 0 (0)                           | 2 (2.4)                            | 1.00     |
| Hyperkeratotic nails                 | 1 (7.7)                         | 1 (1.2)                            | 0.25     |
| Transverse streaking on nails        | 0 (0)                           | 1 (1.2)                            | 1.00     |
| Longitudinal streaking on nails      | 1 (7.7)                         | 10 (11.9)                          | 1.00     |
| Psoriasis                            | 1 (7.7)                         | 4 (4.8)                            | 0.65     |
| Urticaria                            | 0 (0)                           | 3 (3.6)                            | 1.00     |
| Rosacea                              | 1 (7.7)                         | 18 (21.4)                          | 0.30     |
| Acne                                 | 0 (0)                           | 3 (3.6)                            | 1.00     |
| Contact dermatitis                   | 2 (15.4)                        | 4 (4.8)                            | 0.18     |

*Pearson’s chi-square
abnormalities. Cutaneous manifestations are more common in autoimmune thyroid diseases. In our study, skin findings were also more common in patients with autoimmune thyroid disease. Previous studies have shown a relationship between chronic urticaria, vitiligo, alopecia areata and rosacea and thyroid autoimmunity. In our study, chronic urticaria was more common in patients with thyroid disease; but there was no statistically significant difference. There was no another autoimmune skin disease in patients with thyroid disease in our study. Vitiligo and alopecia areata usually occur many years before thyroid dysfunction. Therefore, the presence of high thyroid autoantibodies in these patients may serve as a useful clinical tool to identify patients at risk for thyroid diseases. In summary, alopecia, xerosis, pruritus, diffuse hyperhidrosis, various nail findings and rosacea were more common in patients with thyroid disease in our study. Furthermore, in this study the most common cutaneous manifestations were generally similar to the other studies in not receiving treatment patients with thyroid disease. These results suggested that some cutaneous manifestations may be seen in thyroid disease patients on treatment too.

Study Limitation

Limitations of this study were relatively small sample size, absence of thyroid hormone levels in participants and absence of untreated group.

Conclusion

Various cutaneous manifestations may be seen in patients with thyroid disease on treatment too. We conclude that further studies which comparing thyroid patients on treatment and non-treatment are needed in order to clarify the effect of treatment of thyroid disease on cutaneous manifestations.

Ethics

Ethics Committee Approval: Ethical approval was received from the Eskişehir Osmangazi University, Non-interventional Clinical Research Ethics Committee (approval number: 43, date: 23.07.2019).

Informed Consent: Informed consent was obtained from all participants.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Concept: E.A., E.Ağ., G.Y. Design: E.A., E.Ağ., G.Y., H.K.E., E.S.A., Z.N.S., M.B. Data Collection or Processing: E.A., E.Ağ., G.Y., H.K.E., E.S.A. Analysis or Interpretation: E.A., E.Ağ., G.Y., H.K.E., M.B. Literature Search: E.A., E.Ağ., G.Y., H.K.E., E.S.A. Writing: E.A., E.Ağ., G.Y., H.K.E., E.S.A., Z.N.S., M.B.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Doshi DN, Blyumin ML, Kimball AB: Cutaneous manifestations of thyroid disease. Clin Dermatol 2008;26:283-7.
2. Kasumagic-Halilovic E: Thyroid disease and the skin. Annals Thyroid Res 2014;1:27-31.
3. Ai J, Leonhardt JM, Heymann WR. Autoimmune thyroid diseases: etiology, pathogenesis, and dermatologic manifestations. J Am Acad Dermatol 2003;48:641-62.
4. Burman KD, McKinley-Grant L: Dermatologic aspects of thyroid disease. Clin Dermatol 2006;4:247-55.
5. Artantaş S, Gül U, Kılıç A, Güler S: Skin findings in thyroid diseases. Eur J Intern Med 2009;20:158-61.
6. Özbağçıvan Ö, Akarsu S, Fetil E: Tip II diabetes mellitus ve tiroid hastalıklarında gözlenen deri bulguları ve kararlaştırılması. DEÜ Tip Fakültesi Dergisi 2014;28:7-14.
7. Safer JD: Thyroid hormone action on skin. Dermatoendocrinol 2011;3:211-5.
8. Takir M, Özlü E, Köştek O, et al: Skin findings in autoimmune and nonautoimmune thyroid disease with respect to thyroid functional status and healthy controls. Turk J Med Sci 2017;47:767-70.
9. Puri N: A study on cutaneous manifestations of thyroid disease. Indian J Dermatol 2012;57:247-8.
10. Jabbour SA: Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol 2003;4:315-31.
11. Rostami Mogaddam M, Irandavar Alamdari M, Maleki N, Safavi Ardabili N, Abed Koh S: Evaluation of autoimmune thyroid disease in melasma. J Cosmet Dermatol 2015;14:167-71.
12. Kheradmand M, Afshari M, Damiani G, Abediankenari S, Moosazadeh M: Melasma and thyroid disorders: a systematic review and meta-analysis. Int J Dermatol 2019;58:1231-8.
13. Dogra A, Dua A, Singh P: Thyroid and skin. Indian J Dermatol 2006;51:96-9.
14. Wang SH, Wang J, Lin YS, Tung TH, Chi CC: Increased risk for incident thyroid diseases in people with psoriatic disease: a cohort study. J Am Acad Dermatol 2019;80:1006-12.
15. Berksoy Hayta S, Guner R, Cam S, Akyol M: Rosacea is associated with thyroid autoimmunity: a case control study. Acta Endocrinol (Buchar) 2018;2014:248:51.
16. Kasumagic-Halilovic E, Beslic N, Ovcina-Kurtovic N: Thyroid autoimmunity in patients with chronic urticaria. Med Arch 2017;71:29-31.
17. Kim YS, Han K, Lee JH, et al: Increased risk of chronic spontaneous urticaria in patients with autoimmune thyroid diseases: a nationwide, population-based study. Allergy Asthma Immunol Res 2017;9:373-7.
18. Fan KC, Yang TH, Huang YC: Vitiligo and thyroid disease: a systemic review and meta-analysis. Eur J Dermatol 2018;28:750-63.
19. Lee S, Lee YB, Kim BJ, Lee WS: Screening of thyroid function and autoantibodies in patients with alopecia areata: a systemic review and meta-analysis. J Am Acad Dermatol 2019;80:1410-3.e4.